Asia is rapidly gaining significance in the CRDMO industry and currently has a global share of 21-26%. While China has invested heavily in advanced technologies and infrastructure, fostering research and development (R&D) as well as the development and manufacturing of innovator drugs, India’s contribution remains relatively modest with only a 2–3% share, largely attributable to its sustained focus on generic drug manufacturing.

Source: ICRA Research; *excluding custom manufacturing of generic APIs/ formulations i.e. only includes contract research and custom manufacturing of innovator drugs